Skip to main content
Journal cover image

Troponin T levels and risk of 30-day outcomes in patients with the acute coronary syndrome: prospective verification in the GUSTO-IV trial.

Publication ,  Journal Article
James, S; Armstrong, P; Califf, R; Simoons, ML; Venge, P; Wallentin, L; Lindahl, B
Published in: Am J Med
August 15, 2003

BACKGROUND: A third-generation troponin T assay with improved precision and a lower detection limit has been developed. However, the appropriate cutoff for identifying patients with the acute coronary syndrome who are at low risk of subsequent mortality has not been established. METHODS: A retrospective evaluation of data from the Fragmin and fast Revascularization during InStability in Coronary artery disease II (FRISC-II) trial suggested that a cutoff below 0.1 microg/L for troponin T levels might be more useful in risk stratification. A prospective validation of two cutoff levels (0.03 microg/L and 0.01 microg/L) was performed in 7115 patients with non-ST-elevation acute coronary syndrome from the Global Utilization of Strategies To open Occluded arteries IV (GUSTO-IV) trial. RESULTS: Patients with troponin T levels >0.1 microg/L had greater 30-day mortality (5.5% [201/3679]) than did those with levels

Duke Scholars

Published In

Am J Med

DOI

ISSN

0002-9343

Publication Date

August 15, 2003

Volume

115

Issue

3

Start / End Page

178 / 184

Location

United States

Related Subject Headings

  • Troponin T
  • Syndrome
  • Survival Analysis
  • Sensitivity and Specificity
  • Retrospective Studies
  • Reference Values
  • Prospective Studies
  • Predictive Value of Tests
  • Outcome Assessment, Health Care
  • North America
 

Citation

APA
Chicago
ICMJE
MLA
NLM
James, S., Armstrong, P., Califf, R., Simoons, M. L., Venge, P., Wallentin, L., & Lindahl, B. (2003). Troponin T levels and risk of 30-day outcomes in patients with the acute coronary syndrome: prospective verification in the GUSTO-IV trial. Am J Med, 115(3), 178–184. https://doi.org/10.1016/s0002-9343(03)00348-6
James, Stefan, Paul Armstrong, Robert Califf, Maarten L. Simoons, Per Venge, Lars Wallentin, and Bertil Lindahl. “Troponin T levels and risk of 30-day outcomes in patients with the acute coronary syndrome: prospective verification in the GUSTO-IV trial.Am J Med 115, no. 3 (August 15, 2003): 178–84. https://doi.org/10.1016/s0002-9343(03)00348-6.
James S, Armstrong P, Califf R, Simoons ML, Venge P, Wallentin L, et al. Troponin T levels and risk of 30-day outcomes in patients with the acute coronary syndrome: prospective verification in the GUSTO-IV trial. Am J Med. 2003 Aug 15;115(3):178–84.
James, Stefan, et al. “Troponin T levels and risk of 30-day outcomes in patients with the acute coronary syndrome: prospective verification in the GUSTO-IV trial.Am J Med, vol. 115, no. 3, Aug. 2003, pp. 178–84. Pubmed, doi:10.1016/s0002-9343(03)00348-6.
James S, Armstrong P, Califf R, Simoons ML, Venge P, Wallentin L, Lindahl B. Troponin T levels and risk of 30-day outcomes in patients with the acute coronary syndrome: prospective verification in the GUSTO-IV trial. Am J Med. 2003 Aug 15;115(3):178–184.
Journal cover image

Published In

Am J Med

DOI

ISSN

0002-9343

Publication Date

August 15, 2003

Volume

115

Issue

3

Start / End Page

178 / 184

Location

United States

Related Subject Headings

  • Troponin T
  • Syndrome
  • Survival Analysis
  • Sensitivity and Specificity
  • Retrospective Studies
  • Reference Values
  • Prospective Studies
  • Predictive Value of Tests
  • Outcome Assessment, Health Care
  • North America